Capital investment data from Pitchbook 181 -an online platform for investment data, reveals a steady increase in invested capital and financial deals over the last 20 years for early cancer diagnostics (Figure ). Interestingly, an exception appears to be the capital investment profile from 2019-20, which shows a slight dip in the amount of money invested indicating the reduction in investment during this period (Figure ), the exact reason for which remains unknown. Companies like GRAIL that work on multi-cancer early detection (MCED) testing has raised the highest capital (~$2B) in the last 20 years (Figure ). GRAIL has developed the first clinically validated MCED test -the Galleri® test that can help in early cancer detection of over 50 types of cancers from a single blood draw. Other companies such as Exact Sciences 183 , and Freenome 184 , which work on early cancer detection, have raised a considerable amount of capital investment in the last two decades.